PCI Biotech announces discontinuation of R&D operations and continues evaluation of future options

Oslo (Norway), 8 January 2026 – PCI Biotech (OSE: PCIB). Reference is made to the company’s latest announcement dated 23rd October 2025. The external evaluation of a new bioprocessing technology has been concluded, with no prospects for further collaboration. As PCI Biotech’s limited operations were contingent upon sustained external interest, all R&D operations will now be discontinued.

In recent months, various strategic alternatives have been explored, and this process continues. The evaluation is made with careful consideration of the company’s circumstances, and includes a range of options, including, but not limited to, a merger or a structured wind-up of the company.

The liquidity position of the PCI Biotech group remains critical, and there is no assurance that additional financing can be secured. These material uncertainties cast significant doubt on the PCI Biotech group’s ability to continue as a going concern.

Further information will be communicated as and when appropriate.

PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo, www.pcibiotech.com

Ronny Skuggedal, CEO, email: rs@pcibiotech.no, mobile: +47 9400 5757

Forward-looking statements      
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Ronny Skuggedal, CEO at PCI Biotech Holding ASA, on 8 January 2026 at 14:10 CET.